The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1593
March 9, 2020
View Complete Issue         Table of Contents 2019 
Consensi - A Fixed-Dose Combination of Amlodipine and Celecoxib
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Consensi - A Fixed-Dose Combination of Amlodipine and Celecoxib
March 9, 2020 (Issue: 1593)
Consensi (Coeptis/Burke), a fixed-dose combination of the calcium channel blocker amlodipine (Norvasc, and others) and the COX-2 selective NSAID celecoxib (Celebrex, and generics), has been approved by the FDA for treatment of patients who have...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Consensi - A Fixed-Dose Combination of Amlodipine and Celecoxib
Article code: 1593c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.